摘要
目的探讨凋亡抑制蛋白存活素(Survivin)在晚期非小细胞肺癌(NSCLC)组织中的表达及其与含铂类方案化疗疗效之间的关系。方法应用免疫组化SP法检测82例应用含铂类方案化疗的晚期NSCLC患者癌组织中Survivin蛋白的表达,并结合临床病理指标等进行分析。结果 82例患者中Survivin阳性表达65例(79.3%);Survivin表达与性别、年龄、病理类型、临床分期、化疗有效率、中位生存期无关(P>0.05)。Survivin阳性者1年生存率为23.1%,低于Survivin阴性者的52.9%(P<0.05)。结论 Survivin表达阴性的NSCLC患者应用含铂类方案化疗可能获得生存受益。Survivin表达阳性可能存在铂类药物耐药,Survivin的表达可能成为NSCLC个体化治疗的分子预测指标。
Objective To investigate the expression of Survivin in advanced non-small cell lung cancer （ NSCLC） tissues and its relationship with clinical efficacy and Platinum drug resistance .Methods Immunohisto-chemical S-P method was used to detect the expression of Survivin in 82 patients with NSCLC treated by Platinum therapy.An analysis was conducted based on the Survivin expression and clinical pathological indices .Results Among 82 patients,there were 65 with positive Survivin （79.3%）.The expression of Survivin did not correlate with gender,age,pathological type,clinical stage,effective rate of chemotherapy or median survival time （P〉0.05）.The 1-year survival rate of the patients with positive Survivin was lower than that of the patients with negative Survivin （23.1%vs 52.9%,P〈0.05）.Conclusion The NSCLC patients with negative Survivin might be survival who ben-efit from Platinum therapy .The positive expression of Survivin might indicate Platinum drug resistance , and the ex-pression of Survivin may be an predictive indicator of the individualized treatment of NSCLC .
出处
《广西医学》
CAS
2013年第11期1447-1449,共3页
Guangxi Medical Journal
基金
广西自然科学基金(2010GXNSFA013260)
广西南宁市科学研究与技术开发计划项目(201003045c-6)
